At Nephron Research, our mission is to be essential to our clients’ investment process.
As the market’s leading independent healthcare equity research provider, we strive to separate market noise from the insights that are essential to the investment process.
Nephron’s primary differentiators lie in our research teams and their approach to equity research. The deep experience and insight of our analysts as well as an intense drive to serve a discerning client base sets us apart. With the sole focus of creating value for clients, Nephron can provide a depth of coverage, breadth of access, and consultative services that traditional models lack.
Delivered via an independent and unbiased subscription-only model, Nephron is directly aligned with our client’s interests and investment processes
Meet The Team
At Nephron Research, our experience and connectivity drive deep research products which is supplemented by hyper-relevant corporate access
Process Drives We tackle the most important debates, react quickly, and provide leading perspective
LillyDirect Highlights Opportunity for Pharma, Shortcomings of Pharma Supply Chain
Download
AGBT 2025 Takeaways - NIH Concerns and Genomics Competition in Focus
Download
Next Big Things: Why Pulsed Field Ablation Will Revolutionize the Treatment of AF
Download
Alzheimer’s – A Large, Untapped Dx & Bioprocessing Opp w/ a Lot of Unknowns
DownloadNephron Research Curates Dozens of Events Each Year Designed for Maximum Impact to Client Investment Process
Please join our Health Policy team for the inaugural Nephron D.C. Summit, Wednesday April 15thThe Summit provides an opportunity to engage directly with unique policy experts and opinion leaders you won't find access to elsewhere.
The inaugural Nephron Nashville Summit (June 15-17, 2026) gathers policy leaders, experienced operators, and healthcare-dedicated investors for focused dialogue on payors, providers, facilities, digital health, and the pharma supply chain.
The 2025 Nephron Pharmacy & PBM Innovation Symposium will center on challenges to traditional Pharmacy and PBM business practices with a specific focus on new regulatory and legal threats (i.e.: bipartisan support for federal and state legislation), new pharmacy reimbursement and fulfillment models, and a revamped view of PBM profit pools.
Our independent model and deep healthcare and investment expertise allows us to deliver a full suite of bespoke
and consultative services to investment firms and market participants.
